Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults over 18 years of age.
PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the third quarter.
While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to ...